Daridorexant

Daridorexant (ACT-541468, marketed as Quviviq) is an orally administered, competitive dual orexin receptor antagonist (DORA) approved by the United States Food and Drug Administration in January 2022 and by the European Medicines Agency in April 2022 for the treatment of insomnia disorder in adults. The compound binds both the orexin type 1 receptor (OX1R) and orexin type 2 receptor (OX2R) at sub-nanomolar affinities (Ki 0.47 nM at OX1R, 0.93 nM at OX2R), producing competitive, reversible blockade of the wake-promoting orexin A and orexin B neuropeptides without direct engagement of GABAergic, histaminergic, monoaminergic, or opioid receptor systems. In a selectivity panel of more than 130 central and peripheral pharmacological targets, daridorexant demonstrated no significant off-target binding, a profile that distinguishes it from the benzodiazepines and the Z-drugs (zolpidem, zaleplon, eszopiclone) and that underpins a mechanism-based rationale for preservation of physiological sleep architecture, absence of rebound insomnia on discontinuation, and low liability for tolerance and physical dependence.

The compound was discovered at Actelion Pharmaceuticals Ltd in Allschwil, Switzerland, under the leadership of Jean-Paul and Martine Clozel, and was selected from a large series of benzimidazole-containing dual orexin receptor antagonists on the basis of an optimized pharmacokinetic profile: a terminal elimination half-life of approximately 8 hours, oral bioavailability of 62 percent, rapid absorption (time to peak plasma concentration 1 to 2 hours), and a plasma clearance rate designed to provide full-night sleep coverage at a dose of 25 to 50 mg while minimizing next-morning residual sedation at efficacious doses. When Actelion was acquired by Johnson and Johnson in June 2017, the drug discovery operations (including daridorexant) were spun off into the newly created Idorsia Pharmaceuticals Ltd, which advanced the compound through Phase 2 and Phase 3 clinical development and secured regulatory approval.

Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (Study 1, N=930; Study 2, N=924) conducted at 156 sites in 18 countries demonstrated statistically significant improvements in the co-primary endpoints of wake time after sleep onset (WASO) and latency to persistent sleep (LPS) measured by polysomnography at months 1 and 3. The 50 mg dose additionally improved patient-reported daytime functioning as measured by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), making daridorexant the first insomnia pharmacotherapy to demonstrate improvement on both nighttime sleep parameters and a validated daytime functioning instrument in a registration program. Sleep architecture analysis demonstrated preservation of rapid eye movement (REM) and non-REM sleep stage distributions, with no alteration of electroencephalographic spectral bands in N2, N3, or REM stages and no disruption of sleep spindle activity.

Pharmacokinetics are dominated by hepatic CYP3A4-mediated metabolism, which accounts for approximately 89 percent of metabolic clearance. Protein binding is exceptionally high at 99.7 percent; volume of distribution at steady state is 31 liters; and systemic clearance is 5.0 liters per hour. Concomitant administration with strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) is contraindicated owing to a greater than 400 percent increase in daridorexant exposure; moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole) require dose reduction to 25 mg. The compound is classified as a Schedule IV controlled substance in the United States on the basis of human abuse potential data demonstrating dose-dependent drug-liking effects in recreational sedative drug users, consistent with the scheduling of the other approved DORAs suvorexant and lemborexant.

The safety profile in pivotal trials and in a 40-week extension study (total treatment duration up to 12 months) demonstrated favorable tolerability. The most common adverse events were nasopharyngitis, headache, somnolence, and fatigue, occurring at low incidence. Adverse events of special interest (sleep paralysis, hypnagogic and hypnopompic hallucinations, cataplexy-like symptoms, suicidal ideation) were rare. No evidence of withdrawal symptoms, rebound insomnia, or tolerance was observed on abrupt discontinuation after up to 12 months of treatment. This monograph reviews the chemistry, synthesis, and structural pharmacology of daridorexant; the dual-receptor antagonist mechanism in molecular and functional detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology in rodent and canine models; the clinical evidence base from Phase 1 through Phase 3 and long-term extension; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal analysis; and a comparative assessment of five alternative insomnia pharmacotherapies against daridorexant on five competency standards.